Cargando…

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients

BACKGROUND: Unmanaged cases of obesity might lead to serious conditions and complications, which impair patients’ lives. The aim of this study was to assess the effectiveness and safety of daily 3 mg subcutaneous (s/c) Liraglutide amongst obese non-diabetic patients in Eastern Province, Saudi Arabia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albaker, Waleed, Al Sheikh, Mona, Albakr, Aishah, Alkhafaji, Dania, Al Besher, Eman, Al-Hariri, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627262/ https://www.ncbi.nlm.nih.gov/pubmed/34849008 http://dx.doi.org/10.2147/IJGM.S336904

Ejemplares similares

Association of Sleep, Body Weight and Physical Exercise with Plasma BDNF Levels in Healthy Male Saudi Smokers
por: Al-Mshari, Arwa, et al.
Publicado: (2022)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

Impact of smoking intensities on sleep quality in young Saudi males: a comparative study
por: Al-Mshari, Arwa, et al.
Publicado: (2022)

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
por: Overgaard, Rune V., et al.
Publicado: (2016)

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
por: Wharton, Sean, et al.
Publicado: (2019)

Do Mock Medical Licensure Exams Improve Performance of Graduates? Experience from a Saudi Medical College
por: Al-Sheikh, Mona Hmoud, et al.
Publicado: (2022)

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
por: Wharton, Sean, et al.
Publicado: (2019)

Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
por: Muratori, Fabrizio, et al.
Publicado: (2022)

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
por: Wharton, Sean, et al.
Publicado: (2020)

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
por: Wharton, Sean, et al.
Publicado: (2020)

Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
por: Santini, Sara, et al.
Publicado: (2022)

The impact of obesity on hospitalized patients with COVID-19 infection in the Eastern Province of Saudi Arabia
por: AlKhafaji, Dania, et al.
Publicado: (2022)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
por: Allison, Kelly C., et al.
Publicado: (2022)

Blood Pressure and Cardio-Metabolic Risk Profile in Young Saudi Males in a University Setting
por: EL-Ashker, Said, et al.
Publicado: (2021)

Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers
por: Fujioka, Ken, et al.
Publicado: (2016)

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
por: Ko, Hae-Jin, et al.
Publicado: (2022)

Adiposity and Cardiometabolic Risk assessment Among University Students in Saudi Arabia
por: Albaker, Waleed, et al.
Publicado: (2021)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023)

What is the current status of childhood obesity in Saudi Arabia?: Evidence from 20,000 cases in the Eastern Province: A cross-sectional study
por: Albaker, Waleed, et al.
Publicado: (2022)

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
por: O'Neil, Patrick M., et al.
Publicado: (2017)

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
por: Papathanasiou, Theodoros, et al.
Publicado: (2020)

Improving Adherence to Weight‐Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support
por: Li, Ang, et al.
Publicado: (2020)

Spontaneous Intracerebral Hemorrhage among Hypertensive Patients in Saudi Arabia: Study from a Tertiary Center
por: Albakr, Aishah Ibrahim
Publicado: (2022)

The Impact of Vitamin D Level on the Severity and Outcome of Hospitalized Patients with COVID-19 Disease
por: AlKhafaji, Dania, et al.
Publicado: (2022)

Impact of Knowledge and Practice on Fasting Blood Glucose Levels among Diabetics During Ramadan Fasting
por: Al-Hariri, Mohammed, et al.
Publicado: (2019)

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
por: Wadden, Thomas A., et al.
Publicado: (2020)

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis
por: Konwar, Mahanjit, et al.
Publicado: (2022)

Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
por: Ard, J., et al.
Publicado: (2016)

Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity
por: Kolotkin, R. L., et al.
Publicado: (2017)

Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
por: Tempia Valenta, Silvia, et al.
Publicado: (2023)

Anabolic–Androgenic Steroid Abuse among Gym Users, Eastern Province, Saudi Arabia
por: Albaker, Walied, et al.
Publicado: (2021)

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
por: Blackman, A, et al.
Publicado: (2016)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
por: Papamargaritis, Dimitris, et al.
Publicado: (2020)

Implementing the TRAPD model for the Saudi adaptation of the World Mental Health Composite International Diagnostic Interview 3.0
por: Shahab, Mona, et al.
Publicado: (2019)

Hepatobiliary manifestations of COVID-19 and their impact on severity and outcomes in a single center in Saudi Arabia
por: Al Argan, Reem, et al.
Publicado: (2022)

Clinical reappraisal of the Composite International Diagnostic Interview Version 3.0 in the Saudi National Mental Health Survey
por: Kessler, Ronald C., et al.
Publicado: (2020)

Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study—UPDATES Saudi Arabia
por: AlMalki, Mussa H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p45iflgfiiekluiue6uoh4h63v